APA (7th ed.) Citation

Mooradian, M. J., Reuben, A., Prieto, P. A., Hazar-Rethinam, M., Frederick, D. T., Nadres, B., . . . Sullivan, R. J. (2018). A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. OncoImmunology, 7(5), 1. https://doi.org/10.1080/2162402X.2017.1423172

Chicago Style (17th ed.) Citation

Mooradian, Meghan J., et al. "A Phase II Study of Combined Therapy with a BRAF Inhibitor (vemurafenib) and Interleukin-2 (aldesleukin) in Patients with Metastatic Melanoma." OncoImmunology 7, no. 5 (2018): 1. https://doi.org/10.1080/2162402X.2017.1423172.

MLA (9th ed.) Citation

Mooradian, Meghan J., et al. "A Phase II Study of Combined Therapy with a BRAF Inhibitor (vemurafenib) and Interleukin-2 (aldesleukin) in Patients with Metastatic Melanoma." OncoImmunology, vol. 7, no. 5, 2018, p. 1, https://doi.org/10.1080/2162402X.2017.1423172.